Wolk K, Join-Lambert O, Sabat R. Aetiology and pathogenesis of hidradenitis suppurativa. Br J Dermatol. 2020;183:999–1010.

Article  PubMed  CAS  Google Scholar 

Van Straalen KR, Prens EP, Gudjonsson JE. Insights into hidradenitis suppurativa. J Allergy Clin Immunol. 2022;149:1150–61.

Article  PubMed  Google Scholar 

Garg A, Kirby JS, Lavian J, Lin G, Strunk A. Sex- and age-adjusted population analysis of prevalence estimates for hidradenitis suppurativa in the United States. JAMA Dermatol. 2017;153:760.

Article  PubMed  PubMed Central  Google Scholar 

Midgette B, Garg A. Epidemiology of hidradenitis suppurativa and its comorbid conditions. J Am Acad Dermatol. 2024;91:S3-7.

Article  PubMed  Google Scholar 

Nguyen TV, Damiani G, Orenstein LAV, Hamzavi I, Jemec GB. Hidradenitis suppurativa: an update on epidemiology, phenotypes, diagnosis, pathogenesis, comorbidities and quality of life. J Eur Acad Dermatol Venereol. 2021;35:50–61.

Article  PubMed  CAS  Google Scholar 

Ingram JR. The epidemiology of hidradenitis suppurativa*. Br J Dermatol. 2020;183:990–8.

Article  PubMed  Google Scholar 

Ingram JR, Bettoli V, Espy JI, Kokolakis G, Martorell A, Villani AP, et al. Unmet clinical needs and burden of disease in hidradenitis suppurativa: real-world experience from EU5 and US. J Eur Acad Dermatol Venereol. 2022;36:1597–605.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Sabat R, Alavi A, Wolk K, Wortsman X, McGrath B, Garg A, et al. Hidradenitis suppurativa. Lancet. 2025;405:420–38.

Article  PubMed  CAS  Google Scholar 

Miller IM, Ellervik C, Vinding GR, Zarchi K, Ibler KS, Knudsen KM, et al. Association of metabolic syndrome and hidradenitis suppurativa. JAMA Dermatol. 2014;150:1273.

Article  PubMed  Google Scholar 

Mintoff D, Benhadou F, Pace NP, Frew JW. Metabolic syndrome and hidradenitis suppurativa: epidemiological, molecular, and therapeutic aspects. Int J Dermatol. 2022;61:1175–86.

Article  PubMed  Google Scholar 

Mancuso P. The role of adipokines in chronic inflammation. ImmunoTargets Ther. 2016; 5-47-56. https://doi.org/10.2147/ITT.S73223.

González-López MA, Gonzalo Ocejo-Viñals J, Mata C, Díaz D, Guiral S, Portilla V, et al. Evaluation of serum omentin-1 and apelin concentrationsin patients with hidradenitis suppurativa. Adv Dermatol Allergol. 2021;38:450–4.

Article  Google Scholar 

Boer J. Should hidradenitis suppurativa be included in dermatoses showing koebnerization? Is it friction or fiction? Dermatology. 2017;233:47–52.

Article  PubMed  Google Scholar 

Shalom G, Freud T, Harman-Boehm I, Polishchuk I, Cohen AD. Hidradenitis suppurativa and metabolic syndrome: a comparative cross-sectional study of 3207 patients. Br J Dermatol. 2015;173:464–70.

Article  PubMed  CAS  Google Scholar 

Theut Riis P, Saunte DM, Benhadou F, Del Marmol V, Guillem P, El-Domyati M, et al. Low and high body mass index in hidradenitis suppurativa patients—different subtypes? J Eur Acad Dermatol Venereol. 2018;32:307–12.

Article  PubMed  CAS  Google Scholar 

Bianchi L, Caposiena Caro RD, Ganzetti G, Molinelli E, Dini V, Oranges T, et al. Sex-related differences of clinical features in hidradenitis suppurativa: analysis of an Italian-based cohort. Clin Exp Dermatol. 2019;44:e177–80.

Article  PubMed  CAS  Google Scholar 

Andersen A, Lund A, Knop FK, Vilsbøll T. Glucagon-like peptide 1 in health and disease. Nat Rev Endocrinol. 2018;14:390–403.

Article  PubMed  CAS  Google Scholar 

Lewandowski SL, El K, Campbell JE. Evaluating glucose-dependent insulinotropic polypeptide and glucagon as key regulators of insulin secretion in the pancreatic islet. Am J Physiol-Endocrinol Metab. 2024;327:E103–10.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Wolfe MM, Boylan MO, Chin WW. Glucose-dependent insulinotropic polypeptide in incretin physiology: role in health and disease. Endocr Rev. 2025;46(4):479–500. https://doi.org/10.1210/endrev/bnaf006.

Article  PubMed  PubMed Central  Google Scholar 

Kagdi S, Lyons SA, Beaudry JL. The interplay of glucose-dependent insulinotropic polypeptide in adipose tissue. J Endocrinol. 2024;261:e230361.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Liu QK. Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists. Front Endocrinol. 2024;15:1431292.

Article  Google Scholar 

Bendotti G, Montefusco L, Lunati ME, Usuelli V, Pastore I, Lazzaroni E, et al. The anti-inflammatory and immunological properties of GLP-1 receptor agonists. Pharmacol Res. 2022;182:106320.

Article  PubMed  CAS  Google Scholar 

Hogan AE, Tobin AM, Ahern T, Corrigan MA, Gaoatswe G, Jackson R, et al. Glucagon-like peptide-1 (GLP-1) and the regulation of human invariant natural killer T cells: lessons from obesity, diabetes and psoriasis. Diabetologia. 2011;54:2745–54.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Stoicovy RA, Cora N, Perez A, Nagliya D, Del Calvo G, Lopez TB, et al. Cyclic adenosine monophosphate critically modulates cardiac GLP-1 receptor’s anti-inflammatory effects. Inflamm Res. 2024;73:2043–56.

Article  PubMed  CAS  Google Scholar 

Krajewski PK, Złotowska A, Szepietowski JC. The therapeutic potential of GLP-1 receptor agonists in the management of hidradenitis suppurativa: a systematic review of anti-inflammatory and metabolic effects. J Clin Med. 2024;13:6292.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Al-Badri MR, Azar ST. Effect of glucagon-like peptide-1 receptor agonists in patients with psoriasis. Ther Adv Endocrinol Metab. 2014;5:34–8.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Drucker DJ, Rosen CF. Glucagon-like peptide-1 (GLP-1) receptor agonists, obesity and psoriasis: diabetes meets dermatology. Diabetologia. 2011;54:2741–4.

Article  PubMed  CAS  Google Scholar 

Faurschou A, Pedersen J, Gyldenløve M, Poulsen SS, Holst JJ, Thyssen JP, et al. Increased expression of glucagon-like peptide-1 receptors in psoriasis plaques. Exp Dermatol. 2013;22:150–2.

Article  PubMed  CAS  Google Scholar 

Lal K, Herringshaw E. The use of GLP-1 agonists in the management of cutaneous disease. J Clin Aesthet Dermatol. 2024;17:34–7.

PubMed  PubMed Central  Google Scholar 

Yaseen A, Lahiri SW. Health care provider prescribing habits and barriers to use of new type 2 diabetes medications: a single-system survey study. Clin Diabetes. 2023;41:490–501.

Article  PubMed  PubMed Central  Google Scholar 

Viercinski R, Snively D. Glucagon-like peptide-1 receptor agonists: a pharmacy perspective on insurance coverage and medication access. 2025 [cited 2025 May 5]; Available from: https://info.primarycare.hms.harvard.edu/perspectives/articles/glp-1-pharmacy-perspective

Wilson A. How to get GLP-1 medication through your insurance [Internet]. Ro. 2023 [cited 2025 May 13]. Available from: https://ro.co/weight-loss/how-to-get-glp1-medication-through-insurance/

Medicare Coverage of Anti-Obesity Medications [Internet]. Assistant secretary for planning and evaluation. 2024 [cited 2025 May 8]. Available from: https://aspe.hhs.gov/sites/default/files/documents/127bd5b3347b34be31ac5c6b5ed30e6a/medicare-coverage-anti-obesity-meds.pdf

Latif W, Lambrinos KJ, Patel P, Rodriguez R. Compare and contrast the glucagon-like peptide-1 receptor agonists (GLP1RAs). StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. 2025 [cited 2025 May 7]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK572151/

Boer J, Jemec GBE. Mechanical forces and hidradenitis suppurativa. Exp Dermatol. 2021;30:212–5.

Article  PubMed  Google Scholar 

Kukla A, Hill J, Merzkani M, Bentall A, Lorenz EC, Park WD, et al. The use of GLP1R agonists for the treatment of type 2 diabetes in kidney transplant recipients. Transplant Direct. 2020;6:e524.